lodoxamide tromethamine (alomide) Report issue

Small molecule Orphan Drug FDA Approved FDA
ChEMBL Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer. In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.   Wikipedia

Chemistry

  • SMILES: N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1.NC(CO)(CO)CO
  • InChIKey: KUGJPYZIWCRREB-UHFFFAOYSA-N
  • Mol. Mass: 432.77
  • ALogP: 0.26
  • ChEMBL Molecule:
    lodoxamide tromethamine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$12.6810 - $16.8320
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxoacetic acid), compd. with 2-amino-2- (hydroxymethyl)-1,3-propanediol (1:2) | alomide | alomide allergy | lodoxamide trometamol | lodoxamide tromethamine | u 42585 e | u-42585e | u-42,585e

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Keratoconjunctivitis (approved 1993)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue